HDAC6 and breast carcinoma: Recently, conflicting results were obtained for several cancer cell lines (the human breast cancer cell lines MCF-7, MDA-MB-231, T1-Luc, a mouse breast cancer cell line, SK-OV-3, a human ovarian cancer cell line, and human mesothelioma MSTO-221 h cells) using selective HDAC6 inhibitors (Tubathian A, Tubastatin A, Tubacin, and Ricolinostat) [389].